» Articles » PMID: 30409116

Disease Severity-based Evaluation of Utility Weights for Lung Cancer-related Health States in Korea

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2018 Nov 10
PMID 30409116
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Utility weight, a measure of health-related quality of life, is used in disease burden measurements and economic evaluations. In this study, we used the visual analogue scale (VAS) and standard gamble (SG) method to determine the utility weights of lung cancer health states in South Korea from a societal perspective.

Methods: Six hypothetical health states for lung cancer or a related health state reflective of disease severity were developed: 1) Stage I, 2) Stage II, 3) Stage IIIa, 4) Stage IIIB, 5) Stage IV, and 6) Pulmonary nodule. The description of each health state description was divided into four parts: diagnosis, symptoms, treatment, and progression and prognosis. A total of 515 representative adult Korean participants used a VAS and SG to evaluate these six health states via face-to-face computer-assisted interviews. The means, standard deviations, and median utility weights of the six health states were estimated by valuation method.

Results: The two valuation methods of the scenarios yielded the same mean utility rankings. Pulmonary nodule received the highest rank (VAS, 0.66 and SG, 0.83), whereas Stage 4 was assigned the lowest rank (VAS, 0.09 and SG, 0.31). For all health states, the mean utility weights calculated using the SG were greater than those calculated using the VAS. The differences between the utility weights obtained using the two valuation methods ranged from 0.14 (Stage I) to 0.22 (Stage IV). The two approaches tended to yield larger differences for more severe stages.

Conclusions: This study determined utilities for squamous cell lung cancer that will be useful for estimating the burden of lung cancer and for conducting economic evaluations of lung cancer interventions.

Citing Articles

Health State Utility Values in Early-Stage Non-small Cell Lung Cancer: A Systematic Literature Review.

Jovanoski N, Abogunrin S, Di Maio D, Belleli R, Hudson P, Bhadti S Pharmacoecon Open. 2023; 7(5):723-738.

PMID: 37289325 PMC: 10471534. DOI: 10.1007/s41669-023-00423-0.


Cost Utility Analysis of a Pilot Study for the Korean Lung Cancer Screening Project.

Kim J, Cho B, Kim S, Choi C, Kim Y, Jo M Cancer Res Treat. 2021; 54(3):728-736.

PMID: 34583458 PMC: 9296945. DOI: 10.4143/crt.2021.480.


Health state utility values by cancer stage: a systematic literature review.

Pourrahmat M, Kim A, Kansal A, Hux M, Pushkarna D, Fazeli M Eur J Health Econ. 2021; 22(8):1275-1288.

PMID: 34125315 PMC: 8526485. DOI: 10.1007/s10198-021-01335-8.

References
1.
Hadorn D . The role of public values in setting health care priorities. Soc Sci Med. 1991; 32(7):773-81. DOI: 10.1016/0277-9536(91)90303-t. View

2.
Dolan P, Sutton M . Mapping visual analogue scale health state valuations onto standard gamble and time trade-off values. Soc Sci Med. 1997; 44(10):1519-30. DOI: 10.1016/s0277-9536(96)00271-7. View

3.
Han K, Kim S, Lee S, Park E . Cost-effectiveness analysis of HPV vaccination: comparing the general population with socially vulnerable individuals. Asian Pac J Cancer Prev. 2014; 15(19):8503-8. DOI: 10.7314/apjcp.2014.15.19.8503. View

4.
PARDUCCI A, Wedell D . The category effect with rating scales: number of categories, number of stimuli, and method of presentation. J Exp Psychol Hum Percept Perform. 1986; 12(4):496-516. DOI: 10.1037//0096-1523.12.4.496. View

5.
Ock M, Han J, Lee J, Kim S, Jo M . Estimating quality-adjusted life-year loss due to noncommunicable diseases in Korean adults through to the year 2040. Value Health. 2015; 18(1):61-6. DOI: 10.1016/j.jval.2014.09.008. View